OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Ipsen SA/  FR0010259150  /

Euronext - Paris
2024-04-25  5:35:29 PM Chg. 0.00 Volume Bid3:01:08 AM Ask3:01:08 AM Market Capitalization Dividend Y. P/E Ratio
112.30EUR 0.00% 68,205
Turnover: 7.67 mill.		 111.70Bid Size: 550 113.20Ask Size: 550 9.41 bill.EUR 1.07% 14.27
GlobeNewswire 04-25 GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire 04-24 Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire 04-22 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire 04-15 GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GlobeNewswire 04-10 Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
GlobeNewswire 04-05 GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report ...
GlobeNewswire 04-05 IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
GlobeNewswire 04-04 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 04-02 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire 03-21 CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
GlobeNewswire 03-20 Mountain America Credit Union Partners with Operation Warm to Donate Shoes to Local Children
GlobeNewswire 03-04 Tome Biosciences Forms Science and Technology Advisory Committee
GlobeNewswire 02-29 GENFIT Announces Revenues and Cash Position as of December 31, 2023
GlobeNewswire 02-28 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
GlobeNewswire 02-26 Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as...
GlobeNewswire 02-15 Royalty Pharma Reports Q4 and Full Year 2023 Results
GlobeNewswire 02-13 Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire 02-08 Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to...
GlobeNewswire 02-08 Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswire 01-15 GENFIT Announces 2024 Financial Calendar  
GlobeNewswire 2023-12-12 Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
GlobeNewswire 2023-12-08 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangit...
GlobeNewswire 2023-12-07 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 2023-12-07 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 2023-12-07 Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...